Boehringer Ingelheim expands human biologics manufacturing facility in Fremont, Calif.
Boehringer Ingelheim announced a $217 million investment to upgrade and expand their Fremont manufacturing facility. This investment will bring nearly 300 new high-wage and highly-skilled positions to the city. The site was recently awarded $25.5 million in two separate tax credits from the state, making them the largest award to a pharmaceutical company. This expansion will enable the company to increase its manufacturing capacity by one-third.
"The Bay Area is the largest biotech cluster in the world. We are happy to have made Fremont our home and are grateful for the support we have received from the community and the State of California," said Jens Vogel, President and CEO of Boehringer Ingelheim Fremont, Inc. "We have made a commitment to the region and are excited to continue to invest in the Bay Area and expand our workforce to help increase patient access to high-quality medicines."
Boehringer Ingelheim is a research focused company who invests nearly 20 percent of all net sales back into research and development, which equates to nearly 20 cents on every dollar. The Fremont facility focuses on manufacturing medicines for immunology, rheumatology and oncology.